DAFNA Capital Management’s Neurogene NGNE Stock Holding History

DAFNA Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.8M	Buy	89,032 +32,397	+57%	+$892K	0.53%	37
2026 Q1	$1.14M	Buy	56,635 +28,661	+102%	+$555K	0.26%	56
2025 Q4	$576K	Sell	27,974 -2,401	-8%	-$59.8K	0.13%	67
2025 Q3	$526K	Sell	30,375 -20,721	-41%	-$416K	0.13%	68
2025 Q2	$764K	Sell	51,096 -404	-0.8%	-$6.34K	0.21%	61
2025 Q1	$603K	Hold	51,500	–	–	0.17%	69
2024 Q4	$1.18M	Buy	51,500 +43,725	+562%	+$1.63M	0.3%	54
2024 Q3	$326K	Sell	7,775 -3,225	-29%	-$125K	0.08%	77
2024 Q2	$400K	Buy	+11,000	New	+$388K	0.1%	74
2018 Q2	–	Sell	-5,396	Closed	-$1.52M	–	78
2018 Q1	$1.52M	Sell	5,396 -550	-9%	-$152K	0.74%	39
2017 Q4	$1.4M	Buy	5,946 +1,969	+50%	+$461K	0.75%	40
2017 Q3	$1.13M	Buy	+3,977	New	+$1.14M	0.7%	42
2016 Q4	–	Sell	-1,000	Closed	-$267K	–	70
2016 Q3	$267K	Buy	+1,000	New	+$202K	0.19%	63

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

DAFNA Capital Management's NGNE Position: Q2 2026 in Review

DAFNA Capital Management increased its Neurogene (NGNE) stake by 57% in Q2 2026, buying an estimated $892K and bringing the position to 89,032 shares worth $2.8M. The position accounts for 0.53% of the portfolio, ranked #37.

DAFNA Capital Management first reported a position in NGNE in Q3 2016 and has held it in 13 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

DAFNA Capital Management held 89,032 shares of Neurogene worth $2.8M as of Q2 2026.
DAFNA Capital Management bought 32,397 Neurogene shares in Q2 2026, an estimated $892K.
Neurogene made up 0.53% of DAFNA Capital Management's portfolio in Q2 2026, its #37 holding.
DAFNA Capital Management first reported a position in Neurogene in Q3 2016 and has held it in 13 quarters since.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.